β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS 6974-32-9 Assay ≥99.0% (HPLC) Clofarabine Intermediate High Purity

β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate (CAS 6974-32-9) is an intermediate of (Clofarabine CAS: 123318-82-1). Clofarabine (CAS: 123318-82-1) is a novel purine nucleoside anticancer drugs is first successfully developed by the Top10 biopharmaceutical company of the United States-Genzyme Corporation with the trade names being “Clofarabine”. On December 28, 2004 the US food and Drug Administration (FDA) used fast-track for approval of clofarabine for application to children with refractory or relapsed acute lymphocytic leukemia (ALL); it has an excellent efficacy on the treatment of leukemia with well tolerance and no unpredictable adverse reactions. It can be administrated through either administered intravenously or administered orally. This drug is the first product approved for being dedicated to the treatment of the children's leukemia in more than ten years.